Oak review

Oak sells compounded semaglutide and compounded tirzepatide as weekly injections, and its product pages lead with a low monthly figure. Read the small print under it: that figure is for a 12-month plan. Oak's terms say month-to-month plans and three- and six-month plans exist too, but their prices aren't published; the FAQ says you see your exact price before you pay. So the number on the page is the long-commitment price, not the cost of trying the drug for a month. Ask for the month-to-month price before you choose a plan length.

The commitment matters because of a rule in Oak's terms. If you cancel a multi-month plan that has more than one scheduled payment before its term ends, you repay the discount on the months you've already received. That's the gap between the month-to-month price and your plan price, for each of those months. The charge never exceeds the payments left on the plan, and it doesn't apply if your provider stops or changes your treatment for medical reasons. Even so, a 12-month plan is a 12-month decision. The compounded semaglutide cost guide shows what month-to-month programs charge.

The site emphasizes an online assessment and care-team messaging. Its terms also allow synchronous and asynchronous consultations, so confirm whether your state or clinical situation requires a live visit and how that visit is charged. Oak says you're charged only if a provider approves you, and a declined order is refunded in full. Once a provider approves an order, first fill or refill, it's final and can't be refunded. The terms describe the clinicians as independent and part of a medical group that Oak doesn't name.

On the pharmacy side, Oak says a licensed US compounding pharmacy under state board oversight prepares each order, without naming it in its terms, privacy policy or product pages. Its pages say plainly that compounded drugs aren't FDA-approved, and the site shows a LegitScript certification badge. Brand-name pens and Wegovy tablets are listed too, with prices quoted at checkout. The homepage advertises clinicians licensed in all 50 states, while the terms describe services in 45 states. Clinician-network licensing and product availability are different facts; confirm your exact product and location during the assessment. The compounded semaglutide guide covers the drug.

Oak also markets longevity treatments including NAD+, sermorelin and tesamorelin. A shared account does not mean these products have the same evidence, approval status, pharmacy or cancellation terms as a GLP-1 plan. Ask whether the proposed preparation is an FDA-approved brand or a compounded product, which clinician evaluates it and what its complete recurring price includes. The longevity menu does not identify tesamorelin clearly as a brand product, so do not assume that from the ingredient name. To compare documented weight-care terms with other programs, use the semaglutide lineup and the billing checklist.